Search Within

Adam D Cohen

Formats
  1. Meeting Abstract (22)
  2. Journal Article (19)
  3. Book Section (2)
  4. Book Whole (1)
Groups
  1. Department of Medicine (44)
  2. Hematologic Malignancies, Division of (35)
  3. Center for Hematologic Malignancies (28)
  4. Solid Tumor Oncology Division (21)
  5. GSK Faculty (20)
  6. Melanoma and Immunotherapeutics Service (19)

More Groups

People
  1. Raymond Comenzo (21)
  2. Jedd Wolchok (19)
  3. Hani Hassoun (16)
  4. Alan Houghton (15)
  5. Stephen Nimer (15)
  6. Martin Fleisher (13)

More People

Years
  1. 2021 (1)
  2. 2018 (1)
  3. 2013 (1)
  4. 2011 (1)
  5. 2010 (1)
  6. 2009 (4)

More Years

Publications
  1. Blood (14)
  2. Cancer Research (5)
  3. British Journal of Haematology (4)
  4. Journal of Clinical Oncology (3)
  5. PLoS ONE (3)
  6. Amyloid (1)

More Publications

Publishers
  1. American Society of Hematology (14)
  2. American Association for Cancer Research (5)
  3. John Wiley & Sons (4)
  4. American Society of Clinical Oncology (3)
  5. Elsevier Inc. (3)
  6. Public Library of Science (3)

More Publishers

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Agonist anti-GITR antibody synergizes with cyclophosphamide (CTX) to induce tumor immunity
    Meeting Abstract

    Cohen, A. D.; Hirschhorn-Cymmerman, D. ; Diab, A.; Perales, M. A.; Merghoub, T.; Wolchok, J. D.; Houghton, A. N.
    Cancer Research (2008)

    Fulltext@MSK | Save
  • CD32B expression reflects phenotypic and functional heterogeneity in multiple myeloma (MM)
    Meeting Abstract

    Zhou, P.; Boruchov, A. M.; Hoffman, J. E.; Mo, Q. X.; Olshen, A.; Glasner, E.; Bonvini, E.; Koenig, S.; Drieghe, E.; Fleisher, M.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) results in rapid control of untreated high-risk multiple myeloma (MM) and improves depth of response
    Meeting Abstract

    Landau, H.; Hassoun, H.; Cohen, A.; Hoover, E.; Kewalramani, T.; Boruchov, A.; Klimek, V.; Reich, L.; Riedel, E.; Pandit-Taskar, N.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Early adjuvant treatment after risk-adapted autologous stem cell transplant for systemic light-chain amyloidosis: Increased hospitalizations and impaired immune recovery but improved responses and overall survival
    Meeting Abstract

    Hoffman, J. E.; Hassoun, H.; Landau, H.; Hoover, E.; Cohen, A.; Nimer, S.; Comenzo, R.
    Blood (2008)

    Fulltext@MSK | Save
  • Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
    Journal Article

    Lebovic, D.; Hoffman, J.; Levine, B. M.; Hassoun, H.; Landau, H.; Goldsmith, Y.; Maurer, M. S.; Steingart, R. M.; Cohen, A. D.; Comenzo, R. L.
    British Journal of Haematology (2008)

    Fulltext@MSK | Save
  • High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
    Journal Article

    Hassoun, H.; Flombaum, C.; D'Agati, V. D.; Rafferty, B. T.; Cohen, A.; Klimek, V. M.; Boruchov, A.; Kewalramani, T.; Reich, L.; Nimer, S. D.; more...
    Bone Marrow Transplantation (2008)

    Fulltext@MSK | Save
  • High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [10]
    Journal Article

    Comenzo, R. L.; Steingart, R. M.; Cohen, A. D.
    New England Journal of Medicine (2008)

    Fulltext@MSK | Save
  • Agonist anti-GITR antibody induces CD8 T cell-mediated tumor rejection
    Meeting Abstract

    Cohen, A. D.; Diab, A.; Perales, M. A.; Duan, F.; Jenq, R.; Rizzuto, G.; Hirschorn-Cymmerman, D.; Merghoub, T.; Wolchok, J. D.; Houghton, A. N.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • DNA vaccines against cancer
    Book Section

    Cohen, A. D.; Wolchok, J. D.
    In Kaufman, H. L.; Wolchok, J. D. (Eds.) General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology (2007)

    Fulltext@MSK | Save
  • Efficacy and long term survival of genetically modified T cells targeting CD19 in a syngeneic immune competent transgenic murine tumor model is dependent on prior lymphodepleting chemotherapy
    Meeting Abstract

    Lee, J.; Nikhamin, Y.; Imperato, G.; Cohen, A.; Sadelain, M.; Brentjens, R.
    Blood (2007)

    Fulltext@MSK | Save